Kitov Pharmaceuticals Holdings Ltd (KTOV.OQ)
13 Dec 2017
Get access to over 18 million research reports from over 1,700 sources.
For several years, Reuters.com has provided analyst research reports for downloading. In an effort to streamline our website, analyst research will now be available from our dedicated page for Thomson Reuters On Demand, and the Reuters service will discontinue as of September 30, 2016.
Thomson Reuters On Demand provides over 18 million research reports from 1,700 sources.
Moreover, Thomson Reuters On Demand offers fast and cost-effective solutions that would allow you to retrieve information on:
- private equity
- third-party document and information retrieval
- and much, much more…
Click here to request a report and the team of expert analysts will get back to you shortly, to ensure you get the report you need.
|63||2013||Chairman of the Board & Chief Medical Officer|
|37||2012||Chief Executive Officer, Director|
|65||2013||Chief Financial Officer, Director|
|2016||Vice President - Business Development|
- BRIEF-Kitov pharmaceuticals announces receipt of FDA's favorable response to NT219's pre-ind meeting package
- BRIEF-Kitov Pharmaceuticals announces phase III/IV clinical trial for KIT-302 successfully meets primary endpoint
- BRIEF-Kitov boosts ownership in Tyrnovo and Oncology platform
- BRIEF-Kitov posts filing by FDA of New Drug Application for KIT-302
- BRIEF-Kitov submits new drug application to FDA for KIT-302